Disgruntled long term holders, page-3

Had a quick chat with management and my take on the situation is that:

1) Travelan will re-enter the Chinese market with new disributors and new marketing strategies

2) other trails and clinical work results (Ash, Cdiff Etc) will increase the share price significantly (they are very happy and confident with the current progress)

3) Travelan revenue + significant increase in share price may result in a another cap raise to do Nash P3 alone instead of finding a partner.

4) finally, a takeover by a big US Pharma coy for $500m+

Good luck all!